AI in Drug Discovery Market By Application: Compound Screening, Clinical Trials, By End-Use: Pharmaceutical Companies, Research Institutions, By Region: North America, Europe, Asia Pacific, Segment Forecasts: 2024 - 2030
AI in Drug Discovery Market Trends
The AI in drug discovery market was valued at USD 2.3 billion in 2024 and is projected to grow at a CAGR of 40.5% from 2025 to 2030. The integration of AI technologies in pharmaceutical research is revolutionizing drug development processes, enhancing compound screening and clinical trial efficiency.
Product Insights
Compound screening applications accounted for the largest market share in 2024, contributing 62.3% of total revenue. The ability of AI to analyze vast datasets significantly accelerates the identification of potential drug candidates. Clinical trials are also benefiting from AI-driven patient selection and monitoring, leading to reduced time and costs.
End-Use Insights
Pharmaceutical companies represented the largest end-use segment in 2024, holding a 70.1% market share, as they increasingly adopt AI solutions to streamline their research processes. Research institutions are also leveraging AI for innovative drug development, reflecting a growing trend in collaboration between academia and industry.
Regional Insights
North America dominated the market with a 48.5% share in 2024, driven by a robust pharmaceutical industry and high investments in AI research. The Asia Pacific region is expected to witness the highest growth, with a CAGR of 43.2%, fueled by increasing R&D expenditures and technology adoption in emerging markets
GET A FREE SAMPLE
This FREE sample includes data points, ranging from trend analyses to estimates and forecasts. See for yourself.